Introduction
============

Cancer is a highly heterogeneous disease, not only in terms of variability among patients, but also within a single tumor. This heterogeneity constitutes the main cause for therapy resistance and cancer progression in some patients ([@B110]). We can find different levels of intratumor heterogeneity. First, a tumor is comprised of multiple genotypes, which belong to distinct subclones with diverse features, which may include differential morphology and/or functionality. Additionally, tumors (and the subclones within) are formed of a functionally heterogeneous cell population, where a particular subset of tumor cells have the ability to initiate and propagate tumor growth, survive chemotherapy and drive relapse ([@B238]; [@B75]; [@B164]; [@B124]; [@B255]; [@B308]; [@B183]). These cells, the so-called cancer stem cells (CSCs), have self-renewal capacity, and can give rise to a differentiated progeny, leading to the production of all cell types present within a tumor, thereby generating tumor heterogeneity through a differentiation hierarchy ([@B254]). This distinct population was initially identified in leukemia, but was also found in solid tumors, such as breast, lung, prostate, colon, brain, head and neck, liver, as well as in pancreatic ductal adenocarcinoma (PDAC) ([@B119]; [@B34]; [@B80]). Finally, non-cancer cells present in the tumor microenvironment constitute a third level of heterogeneity, since they can directly affect cancer cell plasticity and functionality ([@B200]; [@B10]).

Cancer stem cells can be originated either from a mutation of a normal stem cell or from differentiated cells acquiring stem-like abilities ([@B254]). Indeed, numerous studies have found an abnormal activation of stem cell regulatory genes and pathways in the CSCs population, such as c-MYC, Bmi-1, Hedgehog, Notch and Wnt ([@B286]; [@B269]; [@B325]). Apart from the well-known developmental pathways such as Wnt, Hedgehog or Jagged, metabolic traits have recently been involved in governing the function of stem cells. Indeed, although stem cells are primarily glycolytic, acquisition of certain metabolic plasticity, together with an increase in oxidative metabolism, primes them for maturation and supports their lineage differentiation ([@B51]; [@B46]; [@B283]). A parallel mechanism was also postulated for CSCs in different tumors ([@B78]; [@B281]; [@B44]). However, recent data indicate that CSCs may mainly depend on oxidative metabolism ([@B269]). In any case, reported metabolic differences between CSCs and progenies introduce another source of heterogeneity within tumors: metabolic heterogeneity. The latter can be further amplified, since different CSCs subclones can bear different metabolic phenotypes ([@B98]) as a result of genetic or microenvironmental factors ([@B106]; [@B247]; [@B268]).

Cancer (Stem) Cell Metabolism
=============================

One of the main cancer characteristics is uncontrolled growth and cell division. To support the abnormal survival and growth, cancer cells need to increase nutrient uptake to supply biosynthesis pathways ([@B312]; [@B143]; [@B118]). To achieve that, cancer cells usually modulate the activity of different metabolic pathways in order to produce metabolic precursors to satisfy energetic and anabolic demands, and maintain redox balance ([@B314]). Due to the crucial contribution of diverse metabolic pathways to malignant transformation and tumor progression, metabolic reprogramming recently became one of the cancer hallmarks ([@B110]).

Aerobic Glycolysis
------------------

The best example of reprogrammed metabolism in cancer is aerobic glycolysis ([@B63]): fast-proliferating tumor cells increase their glucose uptake to produce lactate in the presence of oxygen. This cancer hallmark was discovered by Otto Warburg and, thus, named the Warburg effect ([@B331]; [@B330]; [@B282]; [@B312]; [@B27]). Glycolysis intermediates are used in diverse reactions to support high proliferation rates. For example, glucose-6-phosphate (G6P) can be used in the pentose phosphate pathway (PPP) to produce NADPH ([@B121]; [@B242]; [@B77]; [@B187]) or generate ribose groups, necessary for the synthesis of nucleotides ([@B170]; [@B314]). Alternatively, glycolytic intermediates can be used for anabolic reactions of glycogen or lipid synthesis ([@B100]; [@B159]).

Glycolysis also facilitates survival and fast adaptation to the typically hypoxic tumor environment avoiding toxic Reactive Oxygen Species (ROS) accumulation through both low ROS production and increased detoxification systems ([@B23]; [@B27]; [@B77]; [@B187]). Moreover, favoring glycolysis may bring other advantages to tumor cells, such as creating an acidic environment that can help invasion and suppress the immune response ([@B92]; [@B298]).

Even though aerobic glycolysis is quite inefficient in terms of ATP production, the rate of glucose uptake can be significantly elevated in cancer cells, resulting in ATP production to levels usually achievable with oxidative phosphorylation (OxPhos) ([@B187]). Additionally, although it was originally postulated that aerobic glycolysis is irreversible for tumor cells after cell division ([@B377]; [@B139]; [@B242]), it is well accepted nowadays that most cancers still produce ATP via OxPhos and modulate the contribution of both pathways in response to environmental factors or in different phases of the cell cycle ([@B285]; [@B63]).

Importantly, glycolytic metabolism supports stemness in normal stem cells and CSCs of several cancer types ([@B94]) ([Table 1](#T1){ref-type="table"}). Indeed, recent pieces of evidence demonstrate the involvement of oncogenes and pluripotency transcription factors, such as MYC, p53, K-Ras, HIF1α, NANOG, MEIS1, Wnt or OCT4 in the metabolic reprogramming from oxidative-dependent metabolism to a glucose dependence in many types of cancer (reviewed in [@B95]; [@B3]; [@B73]). Different studies support the glycolysis dependence of CSCs in diverse types of cancer, such as in radioresistant nasopharyngeal carcinoma spheres with high expression of stage-specific embryonic antigen (SSEA) -3 and -4 compared to parental cells ([@B281]), CD133^+^ human hepatocellular carcinoma cells and mouse models ([@B289]; [@B44]), ALDH^+^ (aldehyde dehydrogenase) non-small lung carcinoma cells and side population (SP) cells from human colon cancer ([@B192]).

###### 

Stem-like cells with glycolytic metabolism for various cancer types (in chronological order).

  METABOLIC PHENOTYPE: GLYCOLYSIS                                                                                                                                                   
  --------------------------------- -------------------------------------- ------------------------------------- ------------------------------------------------------------------ ---------
  Glioblastoma                      *In vivo* (xenograft) and *in vitro*   Neurospheres                          Clark-type oxygen electrode                                        [@B374]
  Glioblastoma                      *In vitro*                             Neurospheres                          Gene expression analysis                                           [@B105]
  Breast cancer                     *In vitro*                             Bulk of tumoral cells                 Isotope tracing and seahorse                                       [@B78]
  Glioblastoma                      *In vitro*                             Neurospheres                          Clark-type oxygen electrode                                        [@B359]
  Ovarian cancer                    *In vivo* (xenograft) and *in vitro*   Spheres                               Isotope tracing and seahorse                                       [@B4]
  Breast cancer                     *In vitro*                             Spheres                               Proteomics and targeted metabolomics                               [@B56]
  Ovarian cancer                    *In vitro*                             Spheres                               Isotope tracing combined with spectrometry                         [@B186]
  Lung cancer                       *In vitro*                             SP                                    Clark-type oxygen electrode                                        [@B192]
  Colorectal cancer                 *In vitro*                             SP                                    Clark-type oxygen electrode                                        [@B192]
  Osteosarcoma                      *In vitro*                             3AB-OS CSC-like line                  Seahorse                                                           [@B229]
  Teratocarcinomas                  *In vitro*                             P19SCs                                Clark-type oxygen electrode                                        [@B316]
  Nasopharyngeal carcinoma          *In vitro*                             Sphere-derived cells                  Seahorse                                                           [@B281]
  Hepatocellular carcinoma          *In vitro*                             CD133^+^cells                         Seahorse                                                           [@B289]
  Lung cancer                       *In vitro*                             Spheres                               Glucose uptake, glutamine, glutamate and NAD+/NADH determination   [@B73]
  Breast cancer                     *In vitro*                             Spheres                               Glucose uptake, glutamine, glutamate and NAD+/NADH determination   [@B73]
  Brain cancer                      *In vitro*                             Tumor cell lines with BTIC features   Seahorse                                                           [@B201]
                                                                                                                                                                                    

On the other hand, enhanced glycolysis in CSCs could also constitute a secondary response to maintain energy balance, since reduction of mitochondrial metabolism seems to be essential for full stemness in some cancer types, such as osteosarcoma or glioblastoma ([@B374]; [@B359]; [@B229]). Indeed, the downregulation of mitochondrial genes was associated with enhanced increased expression of genes related to epithelial-mesenchymal transition (EMT) usually linked to stemness ([@B101]). Importantly, such inverse relationship was functionally proven in embryonal carcinoma cells derived from teratocarcinomas, since the stimulation of mitochondrial function induced cell differentiation and loss of pluripotency ([@B316]). In fact, the occurrence of this metabolic switch, not the final glycolytic phenotype, seems to be key for early state of tumorigenesis and acquisition of stemness-related properties in human mammospheres and brain CSCs in a mouse model of primitive neuroectodermal tumors ([@B78]; [@B56]; [@B201]).

Mitochondrial Metabolism
------------------------

Mitochondria play a key role in eukaryotic cells coordinating energy production and distribution through OxPhos based on oxygen and substrate availability, although other important metabolic reactions such as fatty acid oxidation (FAO), glutaminolysis, or reductive carboxylation in cells with damaged mitochondria also take place in these organelles. Mitochondrial tricarboxylic acid (TCA) cycle is primarily fueled by acetyl-CoA produced by glycolysis (from pyruvate) or FAO. Alternatively, in highly glycolytic cells, such as Ras-mutant cells, glutamine can be the driving force for OxPhos ([@B89]) through its conversion to α-ketoglutarate and oxaloacetate, that can be then used for fatty acids (FAs) and nucleotide synthesis ([@B97]). Electron donors produced in the TCA cycle are used by the electron transport chain (ETC) to create a proton motive force to synthesize ATP by the complex V.

As opposed to what we summarized in the previous section, recent literature described OxPhos as the main source of energy in CSCs from a number of cancer types ([Table 2](#T2){ref-type="table"}). This has been convincingly shown for ROS^low^ quiescent CD34^+^ leukemia CSCs ([@B165]), lung spheroids and CD133^+^ PDAC cells ([@B351]; [@B269]), as well as CSCs-enriched spheroids form ovarian, cervical and papillary thyroid carcinoma that displayed a reprogrammed metabolism through TCA cycle ([@B273]; [@B30]). Since mitochondrial metabolism coupled to OxPhos constitutes a much more efficient energy process, CSCs relying on OxPhos would theoretically make a better use of limited nutrients, which is an important advantage to survive in nutritionally poor environments. Indeed, mitochondria-dependent CD44^+^CD117^+^ ovarian CSCs and CD133^+^ PDAC CSCs showed enhanced resistance to glucose or glutamine deprivation compared to their differentiated counterparts ([@B233]; [@B269]). On the other hand, a variety of metabolites released by stromal cells can be used by OxPhos-dependent cells to fuel the TCA cycle, conferring them with increased adaptability to the changing conditions of the tumor microenvironment ([@B4]). The best known example is lactate uptake from hypoxic tumor cells or cancer-associated fibroblasts (CAFs) via monocarboxylate transporter 1 and 2 (MCT1 and MCT2) in a process known as reverse Warburg effect ([@B159]; [@B291]; [@B242]; [@B248]). Moreover, pancreatic stellate cells release alanine to fuel the TCA cycle and subsequent biosynthetic pathways in pancreatic cancer cells ([@B294]). Additionally, recent evidence indicate that microvesicles found in the tumor microenvironment contain several metabolites, including aminoacids, lipids and TCA cycle intermediates to fuel central metabolism of oxidative tumor cells and, consequently, tumor growth ([@B272]; [@B369]). In this sense, stromal cells would play a key role in tumor progression supporting OxPhos-dependent CSCs proliferation and survival in nutrient-deprived environments.

###### 

Stem-like cells with OxPhos metabolism for various cancer types (in chronological order).

  METABOLIC PHENOTYPE: OxPhos                                                                                                                                                                 
  ----------------------------- ------------------------------------------------------------------- -------------------------------------------- -------------------------------------------- ---------
  Lung cancer                   *In vivo* (xenograft) and *in vitro*                                Secondary spheres                            Clark-type oxygen electrode                  [@B351]
  Glioblastoma                  *In vitro*                                                          Gliomaspheres                                Seahorse                                     [@B136]
  Leukemia stem cells           *In vitro*                                                          CD34^+^ cells                                Seahorse                                     [@B165]
  PDAC                          *In vivo* (inducible mouse model of mutated KRAS2) and *in vitro*   Spheres                                      Isotope tracing, metabolomics and seahorse   [@B317]
  Breast cancer                 *In vitro*                                                          Spheres                                      Label-free quantitative proteomics           [@B168]
  PDAC                          *In vivo* (xenograft) and *in vitro*                                CD133^+^ cells and spheres CD44^+^CD133^+^   Seahorse                                     [@B269]
  Ovarian cancer                *In vitro*                                                          Spheres                                      Metabolomics                                 [@B273]
  Papillary Thyroid Carcinoma   *In vitro*                                                          Thyrospheres                                 GCMS                                         [@B30]
                                                                                                                                                                                              

Even though Warburg hypothesized that mitochondrial respiration defects are responsible for cancer cells shifting to glycolysis, it is known today that cancer cells still retain mitochondrial functions and that, in fact, a significant amount of ATP is produced through OxPhos ([@B302]; [@B144]; [@B376]). Indeed, ATP from OxPhos proved to be important for cell movements and invasive/metastatic abilities of cancer (stem) cells ([@B357]), suggesting that mitochondria contributes to cytoskeletal alterations ([@B26]). Moreover, OxPhos activation in metastatic breast cancer models is crucial to escape from the metabolic dormancy derived from hormonal therapy ([@B270]). Interestingly, OxPhos activation is caused by the horizontal transfer of mitochondrial DNA (mtDNA) in exosomes from CAFs to dormant CSCs, providing a possible mechanism to development of resistance to hormonal therapy and highlighting metabolic interaction between CSCs and their niche ([@B271]).

Beyond energy production, mitochondria are involved in controlling cellular redox rate, ROS generation, calcium buffering and the synthesis of intermediate molecules, such as acetyl-CoA and pyrimidines. Additionally, mitochondria have a crucial role in apoptosis initiation through activation of the membrane permeability transport pore, and release of cytochrome C ([@B319]). Furthermore, mitochondria may contribute to malignant transformation and tumor progression through increased ROS production by the ETC ([@B127]; [@B189]), abnormal accumulation of specific mitochondrial oncometabolites modifying epigenetic signals ([@B275]), and functional deficits in apoptosis ([@B306]; [@B133]). For all these reasons, mitochondrial biogenesis is essential for survival and propagation of CSCs regardless of their metabolic phenotype ([@B20]; [@B68]; [@B66]). In fact, mitochondrial biogenesis may be a primary driver of stemness since its inhibition efficiently eliminated hypoxic spheroids in breast cancer ([@B168],[@B169]; [@B65]).

The mechanisms driving mitochondrial biogenesis and OxPhos in CSCs described above have not been fully characterized yet, although some studies shed some light on this matter. In fact, findings in glioblastoma spheroids demonstrated the role of the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (Imp2) in the regulation of OxPhos, and mitochondrial biogenesis and structure ([@B136]). Interestingly, the metabolic profile and plasticity of PDAC CD133^+^ cells rely on the balance between the MYC-driven glycolysis and the main regulator of the mitochondrial biogenesis peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) ([@B269]). In this study, differentiated PDAC cells exhibited an overexpression of MYC that counteracted stemness maintenance through a negative regulation of PGC-1α. These results apparently contradict the role of MYC as driver of stemness via glycolysis previously exposed, which may be due to a cell context-dependent modulation of stemness/differentiation. On the other hand, PGC-1α overexpression can also lead to different outcomes depending on the cellular context in BRAF driven melanomas: increased PGC-1α expression in primary tumors after BRAF inhibition with vemurafenib causes OxPhos addiction associated with poor patient prognosis ([@B111]), while it impaired growth rate and invasive abilities in metastatic settings ([@B195]).

Redox Regulation
----------------

It is well known that oncogenic transformation ([@B310]; [@B371]), dysfunctional mitochondria ([@B160]) and altered cell signaling ([@B299]; [@B251]) induce ROS accumulation in cancer cells, further promoting tumorigenesis and mutagenesis. However, due to the potential deleterious effects of ROS, a powerful antioxidant machinery formed of both enzymatic and non-enzymatic antioxidants is often found in cancers ([@B224]; [@B309]; [@B7]; [@B88]; [@B311]; [@B79]; [@B112]; [@B251]).

Increasing evidence suggests an important role of ROS and redox signaling for CSCs functionality. It was known that quiescent stem cells reside in a low ROS niche that supports their stemness characteristics, like self-renewal capacity. On the other hand, increased ROS content promote stem cell proliferation and differentiation ([@B131]; [@B134]; [@B219]; [@B227]; [@B344]; [@B16]). Only recently, it was shown that CSCs share the same redox-related properties ([@B75]; [@B156]; [@B358]): murine CD44^+^CD24^-/low^Lin^-^ and human Thy1^+^CD24^+^Lin^-^ breast CSCs ([@B75]; [@B196]), CD44^high^ gastrointestinal cell lines ([@B128]), tumorigenic ROS^low^ from head and neck carcinoma cell lines ([@B40]), human or murine CD133^+^ glioblastoma cells from cell lines and tumors and chronic myeloid leukemia (CML) CD34^+^ CSCs ([@B368]; [@B245]; [@B375]) maintain low levels of intracellular ROS coupled to enhanced antioxidant capacity. Apart from stemness maintenance, bearing high antioxidant capacity grants CSCs resistance to ROS inducers, such as chemo and radiotherapy ([@B75]; [@B132]; [@B327]).

Redox balance can also be achieved through the regulation of ROS-dependent signaling pathways and redox-sensitive transcription factors, such as c-MYC, HIF1α, p53, NF-κB, AP-1, and the master regulator of antioxidant response, nuclear factor erythroid 2--related factor 2 (NRF2) ([@B38]; [@B141]; [@B292]; [@B190]; [@B22]; [@B137]; [@B251]). In fact, CSCs regulate ROS levels via antioxidant transcription factors, such as NRF2 or FOXO ([@B75]; [@B375]; [@B338]; [@B263]; [@B40]; [@B196]). Most of these factors affect redox homeostasis by direct or indirect modulation of cellular metabolism. Indeed, NRF2 upregulation in different cancer types ([@B214]; [@B1]; [@B152]; [@B259]; [@B211]) influences the switch between anabolic/catabolic glucose metabolism ([@B214]; [@B319]; [@B117]; [@B113]). In addition, the proto-oncogene c-MYC controls both cellular metabolism and redox homeostasis by increasing glycolysis ([@B84]; [@B153]; [@B321]; [@B212]; [@B115]; [@B62]; [@B206]), and regulating glutamine metabolism ([@B5]). Interestigly, both mechanisms could be interconnected, since c-MYC binds to the NRF2 promoter ([@B174]).

Importantly, most of the main signaling pathways governing CSCs functionality are regulated by ROS signaling. That is the case of stemness-regulatory pathways, such as Wnt and Notch ([@B300]; [@B245]; [@B234]), or key signaling nodes important for cell survival and growth, such as PTEN ([@B340]), PI3K ([@B171]), AKT ([@B373]; [@B74]), ATM ([@B130]; [@B345]), STAT3 ([@B245]; [@B367]), and mammalian target of rapamycin (mTOR) ([@B81]) and their downstream targets. Moreover, those pathways further modulate ROS production/detoxification in a positive feedback loop by activating redox-sensitive transcription factors ([@B215]; [@B307]; [@B81]; [@B353]; [@B367]).

Lipid Metabolism
----------------

Besides the classical metabolic reprogramming related to glucose, alterations in diverse aspects of lipid metabolism are increasingly gaining attention as determinants of cancer, including CSCs function. In fact, highly proliferating cells require increased amounts of the cell membrane's main components: lipids and cholesterol. In that cellular location, lipids function as either membrane building blocks or signaling transduction modifiers, since membrane lipid composition modulates protein recruitment and interaction (lipid rafts) ([@B264]; [@B295]). In this sense, several reports indicate that CSCs accumulate unsaturated lipids, such as monounsaturated FAs (MUFAs), the precursors of several plasma membrane lipids. In fact, lipid desaturation, mainly via the enzyme stearoyl-CoA desaturase (SCD-1), plays essential functions controlling self-renewal and tumorigenicity in different cancer models ([@B223], [@B222]; [@B166]; [@B178]), possibly through the activation of stemness-related pathways, such as Wnt signaling ([@B166]). Additionally, differences in plasma membrane lipid composition between CSCs and their differentiated counterparts have been reported, which can be potentially used to identify CSCs. Indeed, even though CSCs may present an overall decrease in glycosphingolipids as described for the glioblastoma CSC-like cell line GSC11 ([@B114]), the expression of specific gangliosides, such as GD2 and GD3, identified cells with increased self-renewal capacity and tumorigenicity in breast cancer ([@B11]; [@B184]).

Lipids and cholesterol in tumors are either scavenged from exogenous sources or synthesized *de novo* through FA synthase (FASN) or the mevalonate pathway, respectively ([@B13]). Thus, different reports suggest that elevated *de novo* synthesis of lipids and cholesterol contribute to CSCs properties and survival. In fact, the expression of sterol regulatory element-binding protein 1 (SREBP1), master controller of *de novo* lipogenesis, is increased in CD24^-^CD44^+^ESA^+^ cells from a ductal carcinoma *in situ* cell line as well as mammospheres and melanospheres ([@B230]; [@B58]; [@B103]). This transcription factor may be involved in resistance to hypoxia and nutrient scarce environments, as suggested for glioblastoma sphere-derived cells ([@B175]). Moreover, *de novo* lipogenesis from glycolytic intermediates or acetate via FASN is critical for *in vitro* self-renewal ([@B58]; [@B349]), and tumor relapse and metastatic dissemination after withdrawal of anti-angiogenic treatment ([@B293]). In the same line of evidence, the activation of the mevalonate pathway is important for self-renewal and tumor formation in breast and pancreatic cancer, as well as glioblastoma ([@B104]; [@B24]; [@B326]).

Although *de novo* synthesis has traditionally been considered the preferred source of FAs for tumor cells ([@B226]), recent reports highlight the crucial role of FAs uptake via CD36 or FA binding proteins ([@B108]; [@B232]). The same is also true for cholesterol uptake within lipoproteins ([@B107]). Indeed, lipid uptake, either via lipoprotein receptors or CD36, favors proliferation of glioma CD133^+^ cells ([@B108]) and label-retaining/CD44^+^ cells from squamous cell carcinoma ([@B232]). Interestingly, increased lipid uptake points to the crucial role of microenvironment supporting cancer (stem) cell functions: tumor-activated adipocytes provide FAs to support leukemia CD34^+^ cells growth, survival and chemoresistance ([@B350]; [@B277]) as well as omental metastasis from ovarian cancer ([@B221]).

Fatty acids require covalent modification by CoA by fatty acyl-CoA synthetases to enter the bioactive pool of FAs. Afterward, they will be further esterified to form triacylglycerols or sterol esters and stored in lipid droplets (LDs). Importantly, recent reports correlate accumulation of LDs or stored cholesteryl-ester with tumor progression and aggressiveness ([@B360]; [@B107]). In fact, activated and stored lipids play a crucial role supporting tumorigenicity of CSCs *in vivo*, as demonstrated in cells derived from neurospheres from glioblastoma and ALDH^+^ CD133^+^ ovarian cancer cells ([@B296]; [@B210]; [@B179]). This may be a reflect of adaption to the harsh conditions found in the tumor microenvironment, since those lipids can be mobilized upon metabolic stress, providing ATP via FAO to ensure survival ([@B199]). Importantly, increased lipid storage in LDs may constitute a useful CSCs marker, as demonstrated in colorectal (CRC) and ovarian cancer ([@B304]; [@B179]).

Activated FAs are not only incorporated into membranes or storage, but also used as substrate to synthesize signaling lipids or energy production in FAO. Although FAO is considered the main energy source in non-glycolytic tumors ([@B194]; [@B31]), a high activity of this pathway has been reported for aggressive tumor cells and CSCs, especially in nutrient scarce environments ([Table 3](#T3){ref-type="table"}) ([@B32]; [@B142]; [@B60]; [@B233]). In fact, ATP production and survival of matrix-deprived epithelial cells depend on FAO ([@B274]; [@B33]), a metabolic process that also sustains the self-renewal capacity in both leukemia-initiating CFSE^high^CD34^+^ cells and hematopoietic long-term culture initiating cells ([@B267]; [@B129]). Besides its well-known role in energy production, FAs metabolism via mitochondrial FAO regulates multiple functions of CSCs. Indeed, FAO contributes to pluripotency maintenance and chemoresistance ([@B323]), mainly by reducing ROS production ([@B173]; Chen et al., 2016) and may sustain metastatic properties of sphere-derived cells ([@B2]).

###### 

Stem-like cells using alternative metabolism for various cancer types (in chronological order).

  METABOLIC PHENOTYPE: OTHERS                                                                                                                                                                                                                                                                   
  ----------------------------- ----------------------------------------------------------- -------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------- -----------
  Breast cancer                 FAO                                                         *In vitro*                             Detached tumor cells                                                                     Isotope tracing                                                     [@B274]
  Breast cancer                 Ketone bodies                                               *In vivo* (xenograft)                                                                                                           3-OH-butirate effects on tumor growth, migration and angiogenesis   [@B20]
  Hepatic cancer                Glutamine                                                   *In vitro*                             Bulk of tumor cells                                                                      BD Oxygen Biosensor System                                          [@B123]
  Leukemia-initiating cells     FAO                                                         *In vivo* (xenograft) *In vitro*       Bulk of tumor cells                                                                      Clark-type oxygen electrode                                         [@B267]
  Hepatic cancer                Glutamine                                                   *In vitro*                             Bulk of tumor cells                                                                      Glutathione, glutamate and glutamine                                [@B297]
  Breast cancer                 FAO                                                         *In vitro*                             Detached tumor cells                                                                     Isotope tracing                                                     [@B33]
  Leukemia-initiating cells     FAO                                                         *In vivo*                              CD150^+^CD48^-^CD41^-^Flt3^-^CD34^-^KSL cells sorted from Pml^+^/^+^ or Pml^-^/^-^mice   Isotope tracing and seahorse                                        [@B129]
  Glioblastoma                  PPP                                                         *In vitro*                             Gliomaspheres                                                                            Isotope tracing                                                     [@B147]
  Colorectal cancer             Glycolysis, TCA cycle, and cysteine/methionine metabolism   *In vitro*                             CD133^+^ cells                                                                           Metabolomics                                                        [@B48]
  Ovarian Cancer                OXPHOS and PPP                                              *In vivo* (xenografts) *In vitro*      CD44^+^CD117^+^ cells                                                                    Flow cytometry                                                      [@B233]
  PDAC                          Glutamine (non-canonical pathway of glutamine metabolism)   *In vivo* (xenografts) *In vitro*      Spheres                                                                                  Gene expression and enzymatic assays                                [@B177]
  Colorectal cancer             Lysine catabolism                                           *In vivo* (xenografts) *In vitro*      CD110^+^                                                                                 Transcriptomics                                                     [@B339]
  Hepatocellular carcinoma      Glycolysis and FAO in sh-Nanog-TICs                         *In vitro*                             CD133^+^CD49f^+^CD45^-^                                                                  Isotope tracing and metabolomics                                    [@B44]
  Breast cancer                 PPP                                                         *In vitro*                             Mammospheres and ALDH^+^ cells                                                           Glucose consumption, lactate, NADPH and G6P                         [@B70]
  Cervical cancer               TCA                                                         *In vitro*                             Spheres                                                                                  Metabolomics                                                        [@B273]
  Breast cancer                 Mitochondrial biogenesis and FAO                            *In vitro*                             Mammospheres                                                                             Seahorse and label-free semi-quantitative proteomics                [@B65]
  Pancreatic cancer             Glutamine                                                   *In vitro*                             ABCG2 high                                                                               ATP, NADP+/NADPH and glutathione                                    J [@B185]
  Breast cancer                 Ketone bodies                                               *In vitro*                             Mammospheres                                                                             Seahorse                                                            [@B228]
  Brain cancer                  Purine metabolism                                           *In vivo* (xenograft) and *In vitro*   Brain TICs                                                                               Metabolomics                                                        [@B328]
                                                                                                                                                                                                                                                                                                

Finally, lipids can also regulate CSCs functionality in terms of self-renewal and tumorigenic abilities through their function as second messengers in signal transduction pathways, thus becoming potential therapeutic targets. Indeed, sphingolipids, such as sphingosine-1-P (S1P), eicosanoids, such as prostaglandin E2 or glycerophospholipids, such as lysophosphatidic acid (LPA), have been reported to increase CSCs proliferation and *in vivo* tumorigenicity, activating self-renewal and survival signaling pathways (Notch, AKT, NF-kB) in ALDH1^+^ from breast cancer, label-retaining cells in bladder cancer, CD133^+^CD44^+^ cells in CRC and sphere-derived cells from ovarian cancer ([@B120]; [@B161]; [@B320]; [@B276]).

Alternative Fuels
-----------------

Cancer cells require the use of amino acids for their heightened metabolic needs. Indeed, one of the most important metabolic pathways for cancer cells is that related to glutamine ([@B337]), since it is an important substrate for DNA and fatty acid synthesis, as well as anaplerosis of the TCA cycle. Indeed, glutamine addiction has become a hallmark of glycolytic tumors, especially those with increased c-MYC expression ([@B71]; [@B337]; [@B157]). In addition, glutamine is related to glutathione synthesis, well known for its powerful antioxidant ability and some other biological activities ([@B305]; [@B287]). Although OxPhos-dependent pancreatic CD133^+^ CSCs are resistant to glutamine deprivation ([@B269]), evidence of the involvement of glutamine metabolism in the maintenance of the stem-like SP phenotype has been provided in lung and pancreatic cancer by a β-catenin/redox-mediated mechanism ([@B185]). In fact, glutamine deprivation in pancreatic cancer cell lines inhibited their self-renewal capacity, reduced their stemness gene signature and increased sensitivity to radiotherapy ([@B177]). Additionally, aminoacid metabolism, especially glutamine, is increased in acute myeloid leukemia (AML) ROS^low^ CSCs to fuel OxPhos and favor survival ([@B138]). Interestingly, leukemia CSCs may obtain their glutamine supply from neighbor stromal cells, as described for bone marrow adipocytes supporting cancer cells growth after asparaginase treatment in high-risk leukemia patients ([@B82]).

Apart from glutamine, the metabolism of amino acids, such as lysine or serine may also support CSCs features. Indeed, CRC CD110^+^ tumor-initiating cells (TICs) are rich in enzymes implicated in both lysine transport and catabolism, which activates β-catenin-dependent Wnt signaling, ultimately promoting self-renewal and metastasis ([@B339]). Additionally, accumulation of alpha-aminoadipate, an intermediate of lysine catabolism, on brain TICs correlates with poor survival rate of glioblastoma patients, representing a marker of tumor aggressiveness ([@B262]). On the other hand, recent data demonstrate that phosphoglycerate dehydrogenase (PHGDH), catalyzing the first step of the serine biosynthesis, maintains self-renewal and tumorigenicity of lung, breast and brain CD133^high^ sphere-forming cells in a mechanism involving pluripotency gene expression and redox balance ([@B266]; [@B278]). Finally, endogenous tryptophan derivatives, such as Kyn (kynurenine) and ITE (2-(10H-indole-30- carbonyl)-thiazole-4-carboxylic acid methyl ester), may play opposite roles on cancer progression and stemness, regulating OCT4 expression through aryl hydrocarbon receptor (AhR) modulation: accumulation of the low-affinity AhR agonist Kyn in the tumor microenvironment favor carcinogenesis, whereas the high-affinity AhR agonist ITE promotes its binding to the OCT4 promoter to suppress its transcription and, consequently, inducing cell differentiation in U87 glioblastoma neurospheres ([@B50]).

Ketone bodies can also work as fuel to promote tumor growth and play a role in CSCs activity. Reports on breast cancer showed the role of ketone bodies increasing the expression of stemness-related genes, driving recurrence and metastasis, thus related to decreased patient survival ([@B20]; [@B204]).

The PPP has also come up as an alternative way to generate energy in CSCs. For instance, glioblastoma stem-like cells are remarkably metabolically flexibles, switching their metabolism depending on oxygen levels fluctuations: from high levels of PPP activity linked to active proliferation under acute oxygenation, to a glucose-dependent phenotype under hypoxia, when cell migration is stimulated ([@B147]). Additionally, [@B70] described that PPP inhibitors reduced the stemness-related markers in node-positive invasive breast carcinoma and a high rate in PPP activity was also reported in combination with an OxPhos-dependent phenotype in CD44^+^CD117^+^ CSCs from epithelial ovarian cancer ([@B233]).

Overproduction of hyaluronan, a component of the extracellular microenvironment, supports self-renewal in human head and neck squamous cell carcinoma HSC-3 cells ([@B21]) and dedifferentiation in breast cancer cells ([@B43]). Using metabolomic approaches, [@B42] later described that increased hyaluronan production leads to a HIF1α-induced metabolic reprogramming toward glycolysis, thus creating a positive feedback loop through the hexosamine biosynthetic pathway (HBP). Interestingly, HBP inhibition considerably reduced the content of CD44^high^CD24^low^ cells and mammosphere-forming capacity.

Finally, purine metabolism has also been described to regulate stemness-related properties. Indeed, upregulation of MYC-mediated *de novo* purine synthesis maintained self-renewal, proliferation and tumor forming capacity in brain TICs, and was associated with poor prognosis in glioblastoma patients ([@B328]).

Considerations on the Metabolic Heterogeneity of CSCs
-----------------------------------------------------

As inferred from the information above, CSCs display a plethora of metabolic phenotypes diverging from the classical OxPhos/Warburg phenotypes ([Table 3](#T3){ref-type="table"}). However, such diversity cannot be completely attributed to the intrinsic heterogeneity of cancer, since conflicting data can be often found in the literature even for the same tumor entity.

The main source of reported disparities is the utilized model systems. On the one hand, the term CSC tend to be loosely used and include models as dissimilar as established cell lines grown as spheroids in 3D and sorted cells from human tumors expressing one or several surface markers. In fact, although resistance to anoikis and the ability to grow in anchorage-independent conditions are well-accepted characteristics of stem-like cells, the percentage of *bona-fide* CSCs within a spheroid may be as low as 1%. On the other hand, established cell lines are usually clonal and have been passaged *in vitro* for dozens or even hundreds of times: resemblance with the genetic and phenotypic heterogeneity found in tumors barely exists. Even when considering sorted cells from fresh tumors, we need to bear in mind that most surface markers are not completely reliable and may be lost or modified in sample preparation: in fact, trypsinization time may greatly affect expression of these markers. Most importantly, most *in vitro* studies are carried out in artificial metabolic conditions (e.g., high glucose and oxygen) lacking microenvironmental components of the CSC niche. In fact, tumor niche can support metabolic alterations in CSCs ([@B207]; [@B350]) via signaling and metabolic crosstalk.

Interestingly, even with these limitations, different groups have found phenotypically diverse CSCs subpopulations coexisting in the same *in vitro* or *in vivo* conditions ([@B75]; [@B269]; [@B196]). For instance, although most pancreatic CSCs are dependent on OxPhos, a pre-existing subpopulation of CD133^+^ resistant to mitochondrial inhibition, due to their increased metabolic plasticity, was detected ([@B269]). Importantly, differences in metabolism may be associated to functional diversity inside the CSCs population. Indeed, metabolic heterogeneity, mainly in terms of redox state, has been associated to differences in stemness, as well as chemo and radioresistance ([@B75]; [@B329]; [@B269]; [@B350]). Additionally, several reports link CSCs with enhanced metastatic abilities to specific metabolic traits. Indeed, reduced mitochondrial DNA and function contribute to the acquisition of a metastatic phenotype in spheroid-forming breast cancer cells ([@B106]). Moreover, alterations in redox balance leading to NRF2 activation mediate a phenotypic switch from glycolytic mesenchymal-like to OxPhos-dependent epithelial-like breast CSCs ([@B196]). In addition to breast cancer, CD44^+^ESA^low^ cells with increased metastatic potential (upon EMT), linked to low ROS levels, as compared to their non-EMT counterparts, have been described for oral and skin carcinomas, as well as prostate cancer ([@B98]; [@B2]). On the contrary, metastasis-initiating cells in melanoma bear redox stress, as inferred from their elevated ROS and reduced glutathione content ([@B241]; [@B240]).

Therapeutic Targeting of CSCs Metabolism
========================================

Considering the involvement of CSCs in chemoresistance, tumor relapse and metastasis, there is a pressing need in cancer therapy to find new strategies to eradicate this aggressive cell population. As summarized in the previous section, the distinct metabolic features of CSCs, compared to non-CSCs, constitute a significant opportunity to targeting specifically the CSCs component of tumors and eradicate the tumor bulk.

Mitochondrial Metabolism
------------------------

As mentioned above, mitochondria play a key role for CSCs functionality regardless of their dominant metabolic phenotype, suggesting that targeting mitochondrial metabolism may be the most effective therapeutic strategy for their elimination. Noteworthy, highly glycolytic cells with mutations in the TCA cycle or ETC still require functional mitochondria for the generation of metabolites from glutamine via reductive carboxylation ([@B217]). For those reasons, pharmacological approaches designed to target different aspects of mitochondrial function for cancer treatment are currently under intense investigation in preclinical and clinical studies ([Figure 1](#F1){ref-type="fig"}).

![Therapeutic targeting of mitochondrial metabolism in CSCs. Different aspects of the mitochondrial metabolism can be approached to target CSCs: (1) oxidative phosphorylation (OxPhos) can be impaired by ETC inhibitors such as the antidiabetic drugs metformin or phenformin, the reactive oxygen species (ROS) inductor and complex I inhibitor menadione, or the anti-Parkinson compound selegiline; (2) Mitochondrial biogenesis and translation can be targeted by FDA-approved antibiotics such as doxycycline, tigecycline, bedaquiline among others, or non-antibiotic inhibitors; (3) Mitochondrial dynamics can be disrupted by the mitochondrial division inhibitor Mdivi-1; (4) The blockage of mitophagy, an essential mitochondrial quality control system, with nanomedicines such as 188Re-liposome or the inhibitor liensinine may affect CSCs functions; (5) The use of nanocarriers (lipophilic cations, peptides and nanoparticles) conjugated with chemotherapeutics and small drugs may be used for a selective delivery of drugs in mitochondria.](fphar-10-00203-g001){#F1}

### Targeting OxPhos

Inhibition of mitochondrial respiration by compounds blocking ETC complexes is one of the most studied metabolism-based strategies for cancer treatment. In fact, tumor cells in nutrient-deprived environments or displaying limited metabolic plasticity, as described for some gliomaspheres and PDAC CD133^+^ cells ([@B136]; [@B269]), have restricted ability to cope with decreased mitochondrial ATP production. ETC inhibitors also target glycolytic CSCs, such as CD44^+^CD24^low^ cells in breast cancer or SP cells in nasopharyngeal carcinoma ([@B315]; [@B280]), highlighting the importance of ETC for coupled ATP production, avoiding electron loss in the form of ROS.

One of the most studied ETC inhibitors in the context of CSCs targeting is the antidiabetic drug metformin. Reported antitumoral effects of this drug relate to both systemic glucose decrease, and direct cancer cell targeting via ETC complex I inhibition ([@B334]). Although metformin shows cytostatic properties at low concentration, it induces apoptosis specifically in PDAC CD133^+^ cells and CD44^high^ CD24^low^ mammospheres ([@B125]; [@B269]), which, at least for PDAC CD133^+^ cells, is attributable to their dependency on mitochondrial metabolism. Although metformin clinical testing for pancreatic cancer treatment showed no improvement in patient survival rate ([@B158]; [@B253]), positive clinical data has been reported for breast, endometrial and prostate cancer. On the other hand, the development of resistance to metformin monotherapy *in vivo* suggests that the design of combinatory treatments ([@B269]; [@B261]) or the use of stronger mitochondrial inhibitors may be needed. This could be the case of the ETC complex I inhibitor phenformin, which is more efficiently delivered to mitochondria ([@B237]) and when combined with the ALDH inhibitor gossypol, suppresses stemness, invasiveness and cell viability in glioblastoma ([@B231]). Additionally, menadione, with dual mechanism of action combining complex I inhibition and ROS induction, prevents the development of resistance ([@B269]).

Following metformin's relative success, a great effort has been put on the drug repurposing for CSCs targeting in cancer treatment. In this sense, several known FDA-approved antibiotics target the ETC at different levels and have proven to selectively decrease CSC content. This is the case of antimycin A, a powerful complex III inhibitor that decreased lung spheroids ([@B352]); the antituberculosis agent bedaquiline (complex V inhibitor) that targeted mammospheres ([@B90]); oligomycin (another complex V inhibitor), which showed drastic synergistic effects suppressing cell growth and motility in glioblastoma cell lines when combined with 2-deoxy-D-glucose (2DG) ([@B148]); and niclosamide, an antihelmintic with ETC uncoupling properties, that inhibited TICs from ovarian and breast cancers ([@B356]; [@B329]). Similarly, numerous studies suggest the efficacy of the OxPhos inhibitor salinomycin for CSCs targeting *in vitro* and *in vivo* in diverse cancer types ([@B220] and references therein). In this last case, however, the final antitumoral effect may be the result of a combination of factors, since salinomycin also interferes with ABC transporters or Wnt signaling ([@B220]). Besides antibiotics, the agent L-deprenyl (also known as Selegiline), a monoamine oxidase-B (MAO-B) inhibitor typically used for the treatment of Parkinson's disease, was found to exert antimitochondrial activity and cause apoptotic cell death in AML CSCs through the reduction of ETC and glycolysis-related gene expression, independently of MAO-B inhibition ([@B265]).

Considering the therapeutic potential of OxPhos inhibition, compound discovery is currently taking place in order to identify new selective molecules with adequate *in vivo* properties. As an example, the compound VLX600 showed cytotoxicity in colon cancer spheroid-derived cells both *in vivo* and *in vitro*, by directly inhibiting ETC complexes in metabolically compromised microenvironments ([@B366]).

### Targeting Mitochondrial Translation and Biogenesis

As commented above, several FDA-approved antibiotics can disrupt mitochondrial function. Apart from direct OxPhos inhibition, certain widely prescribed antibiotics target either mitochondrial translation or biogenesis as an "off-target" effect ([@B169]), inhibiting self-renewal ability of multiple tumor types ([@B167],[@B168]). For instance, the use of a tetracycline such as doxycycline induced apoptosis in pancreatic cancer cell lines and human cervical carcinoma tumorspheres ([@B288]; [@B347]), while azithromycin (erythromycin family) demonstrated to inhibit the self-renewal capacity of PDAC spheroids ([@B169]). On the other hand, the use of the antimicrobial tigecycline selectively killed leukemia CD34^+^CD38^-^ cells without affecting normal hematopoietic cells through the inhibition of mitochondrial translation ([@B284]).

However, although this research line shows promising results, continuous treatment with antibiotics for cancer therapy may be ineffective ([@B87]). Indeed, long-term desensitization was reported for human metastatic breast cancer cells treated with different antibiotic classes including streptomycin, tetracycline, kanamycin, G418-geneticin (aminoglycoside), puromycine (aminonucleoside) and blasticidine ([@B87]). Nonetheless, the design of novel combinatory treatments or stronger derivatives could overcome this setback for future application in the clinical setting, taking advantage of the well-known safety profile of antibiotics.

On the other hand, non-antibiotic inhibitors of mitochondrial biogenesis are already available: XCT790, a specific inhibitor of the estrogen-related receptor alpha (ERRα)/PGC-1α, signaling pathway (responsible for mitochondrial biogenesis), inhibited breast CD44^+/high^CD24^-/low^ TICs and mammosphere survival and propagation by reducing OxPhos. These effects were prevented or reversed by stimulating mitochondrial biogenesis with the mitochondrial fuel acetyl-L-carnitine (ALCAR9) ([@B68]).

### Targeting Mitochondrial Dynamics

Several types of cancer show downregulation of mitochondrial fusion proteins ([@B364]; [@B47]) or upregulation of fission proteins ([@B252]; [@B145]; [@B336]; [@B365]). In fact, increased mitochondrial fragmentation has also been involved in malignancy, promoting tumor migration and invasion in breast cancer ([@B370]). On the other hand, mitochondrial dynamics seem to regulate proliferation and survival of CSCs, similar to what is known in embryonic stem cells ([@B47]). Indeed, dynamin-related protein 1 (DRP1)-dependent fission regulates mitochondrial distribution in asymmetrical division, ensuring maximal mitochondrial fitness in the daughter stem cell ([@B146]).

Currently, the only available pharmacological strategy to target mitochondrial dynamics is the DRP1 inhibitor mdivi-1. On the one hand, mdivi-1 or DRP-1 knockdown reduced proliferation and induced apoptosis in lung cancer cells, whose mitochondria were in a situation of constant fission *in vitro* and *in vivo* ([@B252]). This inhibitor also attenuates lung cancer and mesothelioma proliferation when combined with the MET inhibitor MGCD516 ([@B322]). Importantly, mdivi-1 reduced tumorsphere-forming ability of breast, lung, and melanoma cancer cell lines ([@B235]) and reduced tumorigenicity of brain TICs *in vitro* and *in vivo* ([@B342]).

### Targeting Mitophagy

Mitophagy is an essential quality control system to selectively remove damaged, non-functional or unnecessary mitochondria in cells. However, its involvement in cancer is controversial, since contradictory reports on the role of this process in tumorigenesis have been published ([@B53]).

On the one hand, the mitophagy promoter Parkin is frequently deleted in many cancer types ([@B35]). In addition, defective mitophagy caused by BNip3 loss/inhibition promote invasion and metastasis in breast, pancreatic or CRC ([@B225]; [@B54]; [@B181]). Moreover, the induction of mitophagy and mitoptosis by salinomycin treatment led to decreased mitochondrial mass and ATP depletion in prostate cancer and breast cancer CD44^high^CD24^low^ cells triggering a cytotoxic effect specific to tumor cells without damaging normal fibroblasts ([@B135]).

On the other hand, mitophagy can be triggered as a stress response against nutrient deprivation or hypoxia, promoting cell survival and tumorigenesis in hostile environments and contributing to drug resistance in human CRC CD133^+^CD44^+^ cells ([@B135]; [@B346]). In agreement with this notion, mitophagy is upregulated in esophageal squamous cell carcinoma undergoing EMT ([@B335]). Accordingly, the use of mitophagy blockers, such as the nanomedicine 188Re-Liposome or the inhibitor liensinine, reversed drug resistance in ovarian cancer cells *in vitro* ([@B39]) and in breast cancer xenografts *in vivo* ([@B372]), respectively. Additionally, the alkaloid matrine induced mitochondrial dysfunction and apoptosis by inhibiting mitophagy in HepG2 hepatoblastoma cells ([@B333]). Interestingly, a link between autophagy and mitochondrial respiration has recently been reported: the novel autophagy inhibitor aumitin blocks complex I activity ([@B258]), while pharmacologic or genetic inhibition of complex I inhibitor impairs autophagy ([@B303]).

### Mitochondrial Drug Delivery

In order to ensure an efficient and selective delivery in mitochondria, different small compounds or chemotherapeutic drugs can be conjugated with nanocarriers, including lipophilic cations, peptides and nanoparticles, with preferential accumulation in mitochondria.

One of the most studied strategies involves the conjugation of small compounds with delocalized lipophilic cations, such as triphenylphosphonium (TPP), dequalinium or rhodamine 123, that possess both lipophilicity and a positive charge, and accumulate in the mitochondrial matrix ([@B218]). Importantly, as OxPhos-dependent CSCs show an elevated mitochondrial membrane potential (ΔΨm), indicative of increased activity ([@B269]), conjugated compounds will be delivered primarily to these cells. For example, MitoChromanol (vitamin E analog) or Gamitrinib (chaperone inhibitor) combined with TPP inhibit OxPhos and ATP production selectively in cancer cells ([@B36]; [@B49]).

Commonly used chemotherapeutic agents can also be joined with lipophilic cations to exert their therapeutic action in the mitochondria and improve their effect. For example, doxorubicin (DOX) combined with TPP showed enhanced toxicity against DOX-resistant MDA-MB-453 breast cancer cells, even though TPP-DOX was as toxic as free DOX in wild type cells ([@B109]). Interestingly, DOX fused with TPP-conjugated chitosan nanoparticles exhibited higher cytotoxicity than free doxorubicin in A549 and Hela cells ([@B122]). Additionally, the development of a cisplatin prodrug combined with TPP showed promising results treating cisplatin-resistant, aggressive cancers, such as neuroblastoma, since its delivery into the mitochondrial matrix circumvents the nucleotide excision repair pathway present in the nucleus ([@B203]). Moreover, the union of paclitaxel with TPP also resulted in enhanced antitumor effects in Hela and in mouse mammary carcinoma cells (4T1) *in vitro* and *in vivo* ([@B17]).

An alternative delivery strategy tested for chemotherapeutic agents involved their conjugation with mitochondria-penetrating peptide (MPP) or mitochondria-targeting sequences (MTS), which act independently of mitochondrial potential. This approach directs their activity toward mtDNA, thus promoting drug selectivity for cancer cells with reduced mtDNA integrity, while their stable mitochondrial location prevents the acquisition of resistance due to drug efflux ([@B37]). As an example, cisplatin linked to MMP overcomes tolerance in cisplatin-resistant ovarian cancer 2780/CP70 cells ([@B203]).

Finally, the combination of the antibiotic salinomycin with reduced graphene oxide-silver nanocomposites synergistically enhanced the activity of either compound alone, leading to mitochondrial dysfunction and selectively killing human ovarian CD133^+^ cells ([@B52]).

Targeting Redox Homeostasis
---------------------------

It is well established that intracellular ROS accumulation induces cancer cell death, a strategy widely used in the clinics associated to classical chemo and radiotherapy. However, recent evidence suggests that this approach may not be effective against CSCs, due to their increased antioxidant potential ([@B75]; [@B128]; [@B358]). Moreover, ROS can be a double-edged sword, since they may promote CSCs survival and invasive abilities acting as signaling molecules ([@B196]).

As previously mentioned, CSCs are characterized by a finely regulated redox metabolism ([@B171]; [@B234]; [@B40]), where glutathione plays an essential role to maintain stemness characteristics ([@B75]; [@B128]). For that reason, increasing oxidative stress by blocking glutathione synthesis could represent a novel therapeutic strategy for eliminating CSCs population and diminishing tumor growth ([@B75]; [@B260]). Thus far, buthionine sulfoximine (BSO), an inhibitor of glutathione biosynthesis, has proven ([@B202]) to be very effective in decreasing clonogenicity and enhancing response of CSCs to radiotherapy *in vitro* and *in vivo* ([@B75]; [@B19]; [@B260]). Due to its importance for glutathione biosynthesis, especially in glutamine-addicted cancer cells, deprivation of glutamine increased oxidative stress and reduced SP cells in non-small lung and pancreatic cancer cell lines ([@B185]). Glutamine deprivation also inhibited metastatic potential of cancer cells, one of the main characteristics of CSCs ([@B324]).

Besides glutathione, strategies aimed at inhibiting cellular antioxidants are currently applied with relative success, mostly improving response to conventional therapies ([Figure 2](#F2){ref-type="fig"}). For example, treatment with auranofin, a thioredoxin reductase inhibitor, increased the sensitivity of human breast CSCs to radiotherapy ([@B260]), while a synergistic reduction of the CD44v9^+^ cells content was achieved by inhibiting glutathione-S-transferase and thioredoxin reductase in patient-derived xenograft (PDX) models of CRC ([@B301]). Arsenic trioxide (ATO), an FDA-approved drug for acute promyelocytic leukemia that increases ROS content and depletes superoxide dismutase (SOD) and glutathione peroxidase (GPX) ([@B180]), proved to reduce CSCs content in different cancer types ([@B76]; [@B182]; [@B41]; [@B12]). Moreover, the synergistic effect of ATO with glutathione depletion could present a novel treatment for cancers unresponsive to ATO treatment alone ([@B213]; [@B61]; [@B15]; [@B208]). The anti-alcohol addiction drug disulfiram has been widely used as anticancer agent since it can increase oxidative stress by blocking SOD activation ([@B28]) and inhibiting NRF2 ([@B343]). In studies with breast cancer cell lines *in vitro* and *in vivo*, disulfiram not only diminished mammosphere formation ([@B355]; [@B154]) and reduced CD44^+^CD24^-^ and CD49f^+^CD24^+^ subpopulations, but also managed to reverse paclitaxel and cisplatin resistance of triple-negative breast cancer (TNBC) ([@B191]). Moreover, disulfiram proved to diminish the ALDH1^+^ population from non-small cell lung cancer cell lines ([@B193]) and CD34^+^CD38^+^ cells in AML cell lines and primary samples *in vitro* and *in vivo* ([@B343]). Now entering phase III in clinical trials, disulfiram may present a potential adjuvant therapy for cancer treatment, although it is highly unstable in blood. For that reason, disulfiram-containing nanoparticles have also been developed. Even though these nanoparticles proved to increase disulfiram blood levels ([@B290]), further studies are needed to establish its full *in vivo* antioxidant and biological properties.

![Therapeutic targeting of glycolysis, lipid and redox metabolism in CSCs. Metabolic pathways such those involving glucose, lipids and redox balance are potentially targetable in CSCs. (1) *Glycolysis*. 2-DG represent the most promising therapeutic approach to neutralize highly glycolytic CSCs in combination treatments. (2) *Lipid metabolism*. 2M14NQ, SSO and the monoclonal antibodies FA6.152 and JC63.1 can block CD36 activity; substances like Etomoxir, Avocatin B or ST136 block fatty acid oxidation (FAO) in the mitochondria; FASN can be inhibited by drugs such as Cerulenin, C75, C93, EGCG, G28UCM, Orlistat, GSK2194069 or GSK837149A; while HMG-CoAR enzyme may be inhibited by either Statins or the combination of Brutieridin plus Melitidin; GTPase prenylation pathway in which mevalonate is involved can be targeted by both Zoledronic acid and GGTL-298; and different steps of the lipid-mediated cell signaling may be blocked with molecules such as S32826, PF8380, Celecoxib, ONOAE-208, Misoprostol, PGE~1~ and ω-3 PUFAs; finally, targeting of the main enzyme of lipid desaturation route, SCD-1, can be achieved by CAY10556, SC-26196, SSI-4, A939572 or MF-438. (3) *Redox metabolism*. Antioxidant features of CSCs may be inhibited at different levels including SOD and GPX proteins with Disulfiram and/or ATO, respectively; ROS-induced NRF2 activity can be neutralized by Disulfiram, ATRA, Brusatol, Apigenin and Trigonelline; finally, glutathione synthesis may be inhibited either directly or indirectly by blocking GS or GLS enzymes with BSO or a glutamine analog, and a mixture of Zaprinast with BPTES or 968 compounds, respectively. 2-DG -- 2-deoxy-D-glucose, Pyr -- pyruvate, LDs -- lipid droplets, LPR -- lipoprotein receptor, FAs -- fatty acids, FASN -- fatty acid synthetase, HMG-CoAR -- 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, SCD-1 -- stearoyl-CoA desaturase, MUFAs -- monounsaturated fatty acids, PUFAs -- polyunsaturated fatty acids, FAO -- fatty acid oxidation, TCA -- tricarbolxylic acid cycle, CPT1 -- carnitine palmitoyltransferase I, GTPase -- guanosin triphosphatase, I/Q/II/III/IV/V -- complexes of the electron transport chain, O~2~^-^ -- superoxide anion, H~2~O~2~ -- oxygen peroxide, SOD -- superoxide dismutase, GPX -- glutathione peroxidase, ROS -- reactive oxygen species, NRF2 -- nuclear factor erythroid 2--related factor 2, GSH -- glutathione, Glu -- glutamate, Gln -- glutamine, GS -- glutathione synthase, GLS -- glutaminase, 2M14NQ -- 2-methylthio-1,4-naphtoquinone, SSO -- sulfosuccinimidyl oleate, mAb -- monoclonal antibody, EGCG -- epigallocatechin gallate, ATRA -- all-trans retinoic acid, BSO -- L-buthionine-S,R-sulfoximine, ATO -- arsenic trioxide.](fphar-10-00203-g002){#F2}

Increased NRF2 levels turned out to play a role in CSCs survival and chemoresistance ([@B162]; [@B375]; [@B263]), representing another potential target for eradicating CSCs. All-trans retinoic acid (ATRA) blocked NRF2 activation, diminishing self-renewal and tumorigenic capacity of ALDH1^+^ lung cancer cells ([@B216]) and ovarian cancer cell lines ([@B150]). Moreover, brusatol, which decreases NRF2 protein levels, was demonstrated to inhibit mammospheres formation and increase the sensitivity of human breast CSCs to Taxol ([@B338]). Similarly, the natural flavonoid apigenin ([@B149]; [@B85]) or the alkaloid trigonelline ([@B6]; [@B261]), which inhibits NRF2 at transcriptional and translational level, can sensitize CSCs toward chemotherapeutic drugs. On the other hand, the combination of ROS inducers and NRF2 (or downstream targets) inhibition could represent a potential strategy for CSCs elimination ([@B75]; [@B128]; [@B163]; [@B193]; [@B154]; [@B150]; [@B196]).

Paradoxically, some natural antioxidants that can increase NRF2 expression levels have also shown therapeutic potential. The NRF2-inducer sulforaphane, a dietary component from broccoli, inhibited self-renewal capacity of CD44^+^ LDH1^+^ pancreatic ([@B249]) and ALDH1^+^ breast cancer cells *in vivo* and *in vitro* ([@B25]). Curcumin, an active ingredient of turmeric, diminished self-renewal capacity of CD44^+^ EpCAM^+^ pancreatic cancer cells *in vitro* and *in vivo* ([@B9]) and reduced proliferation and mammosphere formation of ALDH1^+^ breast cancer cells ([@B140]). Additionally, resveratrol, oleanane triterpenoid or carnosol also proved to active and increase NRF2 expression which could have a positive effect on diminishing the CSCs population ([@B243],[@B244]; [@B269]; [@B102]). Treatment with naturally occurring antioxidants, such as vitamin C or phenethyl isothiocyanates (PEITCs), found in broccoli or Brussel sprouts, also diminished self-renewal capacity and clonogenicity of NCCIT human embryonic carcinoma and human colon cancer cell lines, and reduced CD133^+^, EpCAM^+^ and OV6^+^ cells while inhibiting tumorspheres formation and growth of hepatocellular carcinoma cell lines and PDX models *in vivo* ([@B362]; [@B197]). However, even though natural antioxidants could represent an exciting strategy in anticancer therapy, clinical trials thus far showed no positive effect on patient survival. Indeed, published data highlighted the lack of specificity of antioxidant treatments. This fact, together with the possible contribution of antioxidants to stemness maintenance and cancer development, weakens the translation potential of this approach.

Targeting Lipid Metabolism
--------------------------

Lipid metabolism has become an interesting target in order to design new anti-CSC strategies, and a number of compounds have been tested during the last years ([Figure 2](#F2){ref-type="fig"}).

### Lipid Desaturation

Over the last few years, several SCD-1 inhibitors have demonstrated their effectiveness in different preclinical *in vitro* and *in vivo* models of cancer, by specifically targeting stemness-related properties. Indeed, the inhibitors CAY10556 and SC-26196 reduced stem cell-related markers and signaling pathways by downregulating Hedgehog and Notch expression in ovarian ALDH^+^CD133^+^ cells ([@B179]). Interestingly, this led to the inhibition of sphere formation *in vitro* and tumorigenicity *in vivo*, with no effect on differentiated cells, suggesting the selectivity of this approach. In the same line of evidence, inhibition of SCD-1 with the compounds SSI-4 or A939572 modulates endoplasmic reticulum-stress-mediated differentiation in liver chemoresistant hepatospheres, sensitizing resistant PDXs to sorafenib treatment with low side toxicity *in vivo* ([@B198]). In parallel, effects of the inhibitor A939572 in CD133^+^CD49f^+^ liver CSCs have also been linked to Wnt-mediated self-renewal and *in vivo* tumorigenicity ([@B166]). Finally, MF-438 treatment induced anoikis in lung ALDH1^+^ cells, decreasing self-renewal and pluripotency markers expression ([@B239]). Interestingly, these *in vitro* effects translated into reduced tumorigenic potential and reversion of chemoresistance *in vivo*.

### Lipogenesis

Given the important involvement of the enzyme FASN in numerous tumor types, a number of inhibitors have been designed and/or tested in diverse cancer models: cerulenin, C75, C93, epigallocatechin gallate (EGCG), G28UCM, orlistat, GSK2194069 and GSK837149A. In fact, cerulenin treatment prevents proliferation *in vitro* of pancreatic spheres ([@B24]) and neurospheres established from glioma patients ([@B349]) CSCs. On the other hand, C75 at non-cytotoxic concentrations significantly reduced self-renewal in HER2^+^ breast cancer cells ([@B59]). However, it is important to highlight the critical selectivity and toxicity issues found for FASN inhibitors *in vivo*, which have compromised their translation to clinical trials. Only the inhibitor TVB-2640 is being currently tested in clinical trials for HER2^+^ advanced breast cancer, high grade astrocytoma and colon cancer (NCT03179904, NCT03032484, NCT02980029, respectively).

### Cholesterol Synthesis

Cholesterol synthesis through the mevalonate pathway can be inhibited by statins, for which the molecular target is the enzyme 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-COAR). In fact, treatment with different statins decreased self-renewal and CSCs content in breast ([@B104]) and nasopharyngeal ([@B236]) carcinomas. Interestingly, similar effects were detected in CD133^+^ brain TICs ([@B326]) where overexpression of mevalonate pathway genes was controlled by MYC, highlighting the variety of metabolic pathways controlled by the oncogene. However, anti-CSCs effects of statins could also be related to inhibition of cellular signaling via small GTPases (e.g., Rho and Rac), since they require prenylation using mevalonate pathway intermediates. In fact, impaired self-renewal ability achieved with simvastatin treatment in breast tumorspheres was recapitulated by zoledronic acid and GGTI-298, inhibitors of the prenylation pathway ([@B104]). Moreover, a mixture of brutieridin and melitidin (natural products derived from bergamot with statin-like properties) impaired breast ALDH1^+^ CSCs proliferation inhibiting both FAO and Rho-related signaling pathways ([@B91]).

### Lipid Uptake

Strategies targeting lipid uptake are mainly designed to inhibit the transporter CD36, by either pharmacological inhibition or blocking antibodies. CD36 blockade with 2-methylthio-1,4-naphtoquinone decreases self-renewal ability and induces apoptosis in glioblastoma CD133^+^ ([@B108]). Another CD36 inhibitory compound, sulfosuccinimidyl oleate, decreases chemoresistant leukemic stem cells ([@B350]). Interestingly, CD36-neutralizing antibodies against either all known functions of CD36 (FA6.152) or the ones reported to block active FA and lipoprotein uptake (JC63.1) induced lipotoxicity in label-retaining/CD44^+^ metastasis-initiating cells, thus, inhibiting metastasis initiation and progression in oral squamous cell carcinoma, with no reported toxicity *in vivo* ([@B232]).

### FAO

Fatty acid oxidation inhibition with etomoxir has been studied in preclinical *in vitro* and *in vivo* cancer models. Indeed, etomoxir treatment inhibits mammosphere formation and tumor growth *in vivo* in TNBC tumors bearing high MYC expression ([@B29]). In addition, etomoxir treatment sensitizes hepatocarcinoma CD133^+^CD49f^+^ CSCs to standard chemotherapy with sorafenib ([@B44]). Moreover, etomoxir decreases the number of quiescent leukemia CSCs in AML patients and, combined with the BCl-2 inhibitor ABT-737, substantially decreases tumor burden ([@B267]). However, etomoxir treatment induces normal hematopoietic stem cell exhaustion invalidating this compound for further clinical studies ([@B129]). Interestingly, alternative FAO inhibitors with higher selectivity for malignant cells are under investigation currently. For example, avocatin B is a lipid that accumulates in mitochondria inhibiting FAO and targets AML cells and leukemia CD34^+^ CSCs with no effect on hematopoietic stem cells ([@B172], [@B173]). Additionally, the compound ST136 showed antileukemic activity with no effect on normal CD34^+^ stem cells ([@B256]).

### Lipid-Mediated Signaling

As stated in the previous section, lipid-mediated signaling plays an important role in cancer and, specifically, in CSCs functions. For that reason, several therapeutic approaches, including inhibitors and indirect modulation via dietary supplements, have been studied over the last few years. For example, several stemness-related functions of ovarian spheroid-derived cells from cell lines and primary cells from patients were dependent on LPA synthesis. Thus, inhibition of the LPA-producing enzyme autotaxin with the small molecules S32826 or PF8380 decreased tumorigenicity and chemoresistance *in vivo* ([@B276]). Interestingly, inhibition of LPA production not only affects cancer cells, but could also play an important role modulating the immune system and supporting tumor progression. Indeed, LPA induces the differentiation of monocytes into macrophages and favors the activation of CAFs phenotype ([@B250]; [@B246]).

The most studied lipid mediator class in relation to CSCs is prostaglandins. Indeed, treatment of Apc^Min^/þ mice with celecoxib, the prostaglandin-endoperoxide synthase 2 selective inhibitor, or the EP4 receptor (prostaglandin receptor) antagonist ONOAE-208 resulted in a reduction of tumor CD133^+^CD44^+^ cells and tumor burden ([@B320]). Importantly, celecoxib inhibited CSCs content and the number of liver metastatic tumors upon orthotopic injection of patient-derived CRC into NSG mice. Additionally, celecoxib impaired chemoresistance in bladder carcinomas, suggesting its utility as adjuvant therapy ([@B161]). On the contrary, activation of EP4 with the FDA-approved agonist misoprostol or PGE~1~ reduced CD34^+^ cells in a xenograft model of chronic myelogenous leukemia (CML) ([@B178]), suggesting a context-dependent effect of prostaglandins in stemness.

On the other hand, preclinical and human observational studies suggest that dietary omega-3 polyunsaturated fatty acids (ω-3 PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), decrease CRC risk and may be effective as adjuvant treatment of advanced CRC. Indeed, EPA and DHA reduced the CD133^+^ content or stem properties in two different *in vitro* studies using CRC cell lines ([@B64]; [@B348]). Interestingly, EPA alone or in combination with chemotherapy decreased sphere-forming ability and suppressed tumor growth, likely through inhibition of proinflammatory metabolites in mice ([@B313]). Importantly, studies in other tumor entities also suggest an anti-CSCs effect of ω-3 PUFAs besides CRC. Indeed, EPA and DHA supplementation also reduced proliferation and induced toxicity in breast tumorspheres, likely through alteration of the prostaglandin profile ([@B86]). In addition, a metabolite derived from EPA eradicated leukemia M34^+^Kit^+^Sca1^+^ CSCs in PDXs of CML ([@B116]).

Targeting Metabolism of Alternative Fuels
-----------------------------------------

As mentioned in the previous section, CSCs may utilize a number of different substrates, such as amino acids and ketone bodies, in order to support self-renewal and tumorigenicity. For that reason, diverse compounds which target the metabolism of these alternative fuels are currently under investigation.

On the one hand, the use of a glutamine analog reduced 20 times tumor growth and inhibited metastasis in the VM-M3 murine tumor model of systemic metastasis, when compared with non-treated mice ([@B279]). Interestingly, the anti-asthma compound Zaprinast was identified as a novel glutaminase inhibitor that, together with BPTES and 968, inhibited clonogenicity of pancreatic cancer cells in response to radiation ([@B83]).

Interestingly, [@B228] unveiled the potential anti-CSCs activity of a novel class of compounds denominated "mitoketoscins." These compounds block the active site of the enzymes involved in the recycling of ketone bodies into acetyl-CoA (OXCT1 and ACAT1), leading to inhibition of the CSCs activity and propagation in breast cancer spheroids. However, considering the sometimes contradictory results of diverse studies on the antitumor effects of ketogenic diet (high-fat/low-carbohydrate intake) ([@B318]; [@B332]), the anti-tumor effect of these inhibitors would need to be carefully tested as dependency on ketone bodies strongly varies across tumor entities and specific genotypes.

Combination Treatments: Targeting Glycolysis
--------------------------------------------

Considering the great intratumoral metabolic heterogeneity and plasticity found in tumors, mitochondrial inhibitors as single agents will unlikely become an effective therapy for cancer treatment. In fact, combination treatments, where two or more metabolic pathways are inhibited simultaneously, would block relapse and development of resistances. For instance, a dual inhibition of the main metabolic pathway together with its main escape mechanism will completely erase CSCs within the tumor. This has been reported for the combinations of metformin with either the bromodomain and extraterminal motif (BET) inhibitor JQ-1 in pancreatic cancer ([@B269]) or PI3K inhibition for ovarian cancer ([@B176]), which blocks OxPhos and indirectly inhibits glycolysis simultaneously.

In fact, direct glycolysis inhibition for cancer treatment has been studied intensively in preclinical and clinical settings over the last few years, although with low success rates. On the one hand, glucose transport inhibitors, such as silybin/silibinin \[tested in a phase I/II clinical trials for prostate cancer and advanced hepatocellular carcinoma ([@B93])\], phloretin, WZB117 and fasentin caused important side effects, since GLUT transporters are present in all the cells of the organism. Similarly, inhibition of glycolytic enzymes, such as hexokinase II with lonidamine, has been tested in several types of cancers, including breast, lung and ovarian cancer ([@B96]; [@B67]; [@B69]; [@B14]). However, there was no significant improvement in overall survival and many cases presented with elevated toxicity. Additionally, the glucose analog 2-DG was shown to be a promising agent in preclinical studies ([@B205]; [@B57]). In fact, it has been recently tested in phase II/III of a clinical trial for prostate cancer (NCT00633087), although no results are available, since the trial was terminated due to the slow accrual.

Apart from direct inhibition, targeting tumor drivers affecting cellular metabolism might hinder glycolysis. For example, KRAS mutation is present in more than 90% of pancreatic cancer cases ([@B8]) and controls both tumorigenesis and metabolic reprogramming ([@B354]; [@B287]; [@B189]). In fact, KRAS drives glycolysis and the diversion of glycolysis intermediates into the non-oxidative branch of PPP, essential for the synthesis of nucleic acids ([@B361]; [@B354]; [@B18]). However, even though small molecule inhibitors of KRAS proved to be promising in preclinical studies ([@B341]; [@B363]), targeting KRAS or its downstream pathways showed no effect in overall survival and overall response rate in pancreatic cancer patients ([@B155]; [@B126]; [@B55]).

Alternatively, c-MYC is another essential driver of tumorigenesis and glycolysis in cancer ([@B212]; [@B188]; [@B115]). For that reason, different compounds targeting MYC are currently undergoing clinical trials. Noteworthy, inhibitors of BET proteins directly downregulate MYC expression and suppress tumor growth *in vivo* ([@B72]; [@B209]; [@B99]). Importantly, since MYC suppression blocks development of resistance to mitochondrial inhibitors ([@B269]; [@B151]), combinatory approaches using this strategy can represent a promising anticancer therapy.

Concluding Remarks
==================

Over the last few years, a huge collective effort to decipher metabolic reprogramming occurring in cancer has taken place. Technical advances have allowed the determination of the great metabolic heterogeneity, not only among individuals suffering from one type of cancer, but within a single tumor. Collectively, present literature indicates that both metabolic and redox state diversity define CSCs phenotype and fate, determining response to therapy. Importantly, most of the metabolic dependencies described for CSCs in diverse tumor entities have the tight control of redox state as a common factor ([Figure 3](#F3){ref-type="fig"}), unveiling an important vulnerability that could provide new therapeutic opportunities. Other factors, such as tumor metabolic heterogeneity, microenvironmental cues or a cross-talk through metabolic and redox signaling between CSCs and cancer cells or stromal components ([@B257]; [@B45]; [@B40]; [@B196]) can play an additional role in cancer progression and chemoresistance. Therefore, current knowledge suggests that carefully designed therapies, which target metabolically diverse populations and consider the tumor microenvironment may be crucial in order to develop more effective metabolism-focused treatment strategies.

![Redox involvement in the different metabolic dependencies described for CSCs. CSCs bear diverse metabolic dependencies in a tumor and context-dependent manner: (1) Aerobic glycolysis, controlled by MYC; (2) OxPhos, fuelled by different microenvironmental substrates and controlled by Imp2 or PGC-1α; (3) Lipid metabolism, increasing either fatty acid synthesis and storage in lipid droplets (LDs) or utilization via mitochondrial FAO; (4) CSCs can be dependent on alternative substrates and pathways such as aminoacids, ketone bodies, PPP or purines. Interestingly, the metabolic phenotypes described for CSCs ensure the maintenance of cellular redox state. Keeping redox balance is crucial for CSCs in order to maintain their stemness characteristics, differentiation ability and resistance to chemo and radiotherapy, constituting one of the most important vulnerabilities independently of their origin or cellular context. ROS -- reactive oxygen species, OxPhos -- oxidative phosphorylation, LDs -- lipid droplets, PPP -- pentose phosphate pathway, FAO -- fatty acid oxidation, TCA -- tricarboxylic acid cycle.](fphar-10-00203-g003){#F3}
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α-ADD

:   alpha-aminoadipate

2DG

:   2-deoxy-D-glucose

AML

:   acute myeloid leukemia

ALDH1

:   aldehyde dehydrogenase 1

ATO

:   arsenic trioxide

BET

:   bromodomain and extra-terminal motif

BSO

:   buthionine sulfoximide

CAFs

:   cancer associated fibroblast

CML

:   chronic myeloid leukemia

CSCs

:   cancer stem cells

DHA

:   docosahexaenoic acid

DOX

:   doxorubicin

DQA

:   dequalinium

DRP-1

:   dynamin-related protein 1

EGCG

:   epigallocatechin gallate

EPA

:   eicosapentaenoic acid

ERRα

:   estrogen-related receptor alpha

EMT

:   epithelial-mesenchymal transition

ETC

:   electron transport chain

FAs

:   fatty acids

FAO

:   fatty acid oxidation

FASN

:   fatty synthase

FOXO

:   forkhead box

G6P

:   glucose-6-phosphate

GPx

:   glutathione peroxidase

HBP

:   hexosamine biosynthetic pathway

LDs

:   lipid droplets

LPA

:   lysophosphatidic acid

MAO-B

:   monoamine oxidase-B inhibitor

MCT 1/2

:   monocarboxylate transporter 1 and 2

Mdivi-1

:   mitochondrial division inhibitor

MPP

:   mitochondria penetrating peptide

mtDNA

:   mitochondrial DNA

mTOR

:   mammalian target of rapamycin

MTS

:   mitochondria targeting sequences

MUFAs

:   monounsaturated fatty acids

NER

:   nucleotide excision repair

NRF2

:   nuclear factor erythroid 2--related factor 2

OxPhos

:   oxidative phosphorylation

PDAC

:   pancreatic ductal adenocarcinoma

PDX

:   patient-derived xenograft

PEITCs

:   phenethyl isothiocyanates

PGC-1α

:   peroxisome proliferator-activated receptor gamma coactivator 1-alpha

PHGDH

:   phosphoglycerate dehydrogenase

PI3K

:   phosphoinositide 3-kinase

PPP

:   pentose phosphate pathway

ROS

:   reactive oxygen species

S1P

:   sphingosine-1-P

SOD

:   superoxide dismutase

SREBP1

:   sterol regulatory element-binding protein 1

SCD-1

:   stearoyl-CoA desaturase

TCA

:   tricarboxylic acid

TICs

:   tumor initiating cells

TNBC

:   triple negative breast cancer

TPP

:   triphenylphosphonium
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